A single-blind, randomised, placebo-controlled, 15 day repeated-dose study to evaluate the safety, tolerability and pharmacokinetics of SB-649868 [GSK 649868] and its interaction with the CYP3A4 isoenzyme in healthy male subjects.

Trial Profile

A single-blind, randomised, placebo-controlled, 15 day repeated-dose study to evaluate the safety, tolerability and pharmacokinetics of SB-649868 [GSK 649868] and its interaction with the CYP3A4 isoenzyme in healthy male subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs GSK 649868 (Primary) ; Simvastatin
  • Indications Sleep disorders
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top